Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors

Nishio Makoto; Satouchi Miyako; Horiike Atsushi; Horio Yoshitsugu; Sunaga Yoshinori; Ecstein-Fraisse Evelyne; Hida Toyoaki

首页> 外文期刊>Japanese journal of clinical oncology. >Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors

【24h】

Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors

机译：第1期关于多西紫杉醇和顺铂的日本晚期实体瘤患者联合的研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The combination use of the vascular disrupting agent ombrabulin with chemotherapeutic agents was previously shown to be highly synergistic in preclinical models.

机译：背景：血管破坏剂Ombrabulin的组合使用具有化学治疗剂的橡木蛋白在临床前模型中被证明是高度协同的。

著录项

来源
《Japanese journal of clinical oncology.》 |2018年第4期|共7页
作者
Nishio Makoto; Satouchi Miyako; Horiike Atsushi; Horio Yoshitsugu; Sunaga Yoshinori; Ecstein-Fraisse Evelyne; Hida Toyoaki;
展开▼
作者单位

Japanese Fdn Canc Res Canc Inst Hosp Tokyo Japan;

Hyogo Canc Ctr Akashi Hyogo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Tokyo Japan;

Aichi Canc Ctr Hosp Nagoya Aichi Japan;

Sanofi 640 Mem Dr Cambridge MA USA;

Sanofi 54 Rue Boetie Paris France;

Aichi Canc Ctr Hosp Nagoya Aichi Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
ombrabulin; vascular disrupting agent; docetaxel; cisplatin Japanese patients;

机译：Ombrabulin;血管破坏剂;多西紫杉醇;顺铂日本患者;

相似文献

外文文献
中文文献
专利

1. Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors [J] . Nishio Makoto, Satouchi Miyako, Horiike Atsushi, Japanese journal of clinical oncology. . 2018,第4期

机译：第1期关于多西紫杉醇和顺铂的日本晚期实体瘤患者联合的研究
2. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors [J] . Bahleda Rastislav, Sessa Cristiana, Del Conte Gianluca, Investigational new drugs. . 2014,第6期

机译：ombrabulin（AVE8062）与顺铂/多西他赛或卡铂/紫杉醇联合治疗晚期实体瘤的I期临床和药代动力学研究
3. An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. [J] . H Murakami, T Kurata, Y Onozawa, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：在日本患有晚期实体瘤的患者中，开放性，剂量递增，安全性和药代动力学的ombrabulin（一种血管破裂剂）研究处于第一阶段，每3周静脉输注30分钟。
4. Intralesional Calcium Phosphate/cisplatin Therapy Of Solid Tumors [C] . L. Kuhn, A. Deliso, J. Bordonaro Society for Biomaterials Transactions of the 30th Annual Meeting amp; Exposition vol.28: New Applications and Technologies; 20050427-30; Memphis,TN(US) . 2005

机译：实体瘤内磷酸钙/顺铂疗法
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. An open-label dose-escalation safety and pharmacokinetics phase I study of ombrabulin a vascular disrupting agent administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, -1

机译：一项开放性剂量递增安全性和药代动力学I期研究ombrabulin（一种血管破裂剂）每3周对日本晚期实体瘤患者进行30分钟静脉输注
7. Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors [O] . Makoto Nishio, Miyako Satouchi, Atsushi Horiike, 2018

机译：第1期关于多西紫杉醇和顺铂的日本晚期实体肿瘤患者联合的研究

Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅